Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications
Shots:
- CytomX to receive $80M up front- ~$1.6B as pre/ clinical & commercial milestones- along with royalties on sales and will be responsible for research and discovery activities- up to clinical candidate selection
- The companies partnered for several initial programs and will utilize CytomX’s Probody therapeutic technology for CD3 bispecific targets and its expertise in targeting multiple Ab modalities to the tumor micro-environment
- For a specified number of targets- prior to the initiation of the first clinical study- CytomX to get an option to fund a pre-determined portion of development cost and may receive a pre-specified portion of profits in the US and royalties on sales (ex-US) and may later exercise its option for co-commercialization rights in the US
Click here to read full press release/ article | Ref: PRNewswire | Image: Astellas
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
